Literature DB >> 2232624

New approaches in the treatment of the dystonias.

N Diederich1, C G Goetz, C L Comella.   

Abstract

At this point the treatment of dystonias remains highly empirical. Secondary dystonias, especially those related to specific drug treatment, have to be ruled out carefully. A few dystonic subgroups respond well to levodopa medication. In the other syndromes, anticholinergics are the usual first choice. In focal conditions botulinum toxin injections seem to be the most effective regimen, although there are only a few long-term studies. Surgical procedures are an ultimate option.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2232624     DOI: 10.1007/bf01646651

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  59 in total

1.  Dose standardisation of botulinum toxin.

Authors:  N Quinn; M Hallett
Journal:  Lancet       Date:  1989-04-29       Impact factor: 79.321

2.  Distant effects of locally injected botulinum toxin: incidence and course.

Authors:  D J Lange; M F Brin; S Fahn; R E Lovelace
Journal:  Adv Neurol       Date:  1988

3.  PET studies of cerebral glucose metabolism in idiopathic torticollis.

Authors:  A J Stoessl; W R Martin; C Clark; M J Adam; W Ammann; J H Beckman; M Bergstrom; R Harrop; J G Rogers; T J Ruth
Journal:  Neurology       Date:  1986-05       Impact factor: 9.910

4.  Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias.

Authors:  J Jankovic; J Orman
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

5.  Botulinum toxin in spasmodic torticollis.

Authors:  R Stell; P D Thompson; C D Marsden
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

6.  Long-term results of stereotactic treatment of spasmodic torticollis.

Authors:  F Mundinger; T Riechert; J Disselhoff
Journal:  Confin Neurol       Date:  1972

7.  High dose anticholinergic therapy in adult dystonia.

Authors:  A E Lang
Journal:  Can J Neurol Sci       Date:  1986-02       Impact factor: 2.104

8.  Effectiveness of botulinum toxin therapy for essential blepharospasm.

Authors:  P F Engstrom; J B Arnoult; M L Mazow; T C Prager; R B Wilkins; W A Byrd; R J Hofmann
Journal:  Ophthalmology       Date:  1987-08       Impact factor: 12.079

9.  Controlled trial of botulinum toxin injections in the treatment of spasmodic torticollis.

Authors:  D J Gelb; D H Lowenstein; M J Aminoff
Journal:  Neurology       Date:  1989-01       Impact factor: 9.910

10.  DOPA-sensitive progressive dystonia of childhood with fluctuations of symptoms--Segawa's syndrome and possible variants. Results of a collaborative study of the European Federation of Child Neurology Societies (EFCNS).

Authors:  T Deonna
Journal:  Neuropediatrics       Date:  1986-05       Impact factor: 1.947

View more
  1 in total

1.  Novel VPS13A Gene Mutations Identified in Patients Diagnosed with Chorea-acanthocytosis (ChAc): Case Presentation and Literature Review.

Authors:  Yan Shen; Xiaoming Liu; Xi Long; Chao Han; Fang Wan; Wenliang Fan; Xingfang Guo; Kai Ma; Shiyi Guo; Luxi Wang; Yun Xia; Ling Liu; Jinsha Huang; Zhicheng Lin; Nian Xiong; Tao Wang
Journal:  Front Aging Neurosci       Date:  2017-04-12       Impact factor: 5.750

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.